The first new drugs to be developed in 50 years were the last chance for some people with extensively drug-resistant tuberculosis (XDR-TB) in the Chechen Republic of the Russian Federation. In 2015, MSF’s Maria Borshova spoke to patients who had just started their new two-year-long treatments. She recently met them again.

Médecins Sans Frontières urges governments to step up the use of newer TB drugs.

Médecins Sans Frontières (MSF) Access Campaign is opening the position of TB Advocacy Officer.

Global attention needed to prevent and treat AIDS in antiretroviral era, with 50% of hospital admissions in MSF hospitals already on treatment and showing clinical signs of failure; TB and cryptococcal meningitis remain HIV patients’ primary comorbidities.

Ahead of the G20 Summit in Hamburg, where global health is on the agenda for the first time, the international medical humanitarian organisation Médecins Sans Frontières (MSF) called on G20 leaders to follow through on the declaration made by their health ministers in late May.

New MSF report shows slow progress in adopting and implementing key TB prevention, testing and treatment policies and practices.

Médecins Sans Frontières: Open letter from MSF to the Meeting of the G20 Health Ministers

Médecins Sans Frontières (MSF) urges Sequella and Pfizer to provide open access to all existing clinical data for sutezolid to help accelerate the research and development of urgently needed new, lifesaving TB treatment regimes.

Companies and countries must take urgent action to increase access to these life-saving treatments.